Ventyx Biosciences Inc (VTYX) USD0.0001

Sell:$1.30Buy:$1.31$0.14 (11.54%)

NASDAQ:0.01%
Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.31
Change:$0.14 (11.54%)
Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.31
Change:$0.14 (11.54%)
Prices delayed by at least 15 minutes

Company Information

About this company

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Key people

Sheila Gujrathi
Executive Chairperson of the Board
Raju Mohan
President, Chief Executive Officer, Founder, Director
Roy M. Gonzales
Interim Principal Financial Officer, Interim Principal Accounting Officer
Matthew Moore
Chief Operating Officer
John M. Nuss
Chief Scientific Officer
Onaiza Cadoret - Manier
Independent Director
Allison J. Hulme
Independent Director
Somasundaram Subramaniam
Independent Director
William R. White
Independent Director
Click to see more

Key facts

  • EPIC
    VTYX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92332V1070
  • Market cap
    $86.11m
  • Employees
    79
  • Shares in issue
    71.16m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.